Information Provided By: 
Fly News Breaks for April 20, 2015
HSP, MDCO, EGRX
Apr 20, 2015 | 07:02 EDT
Piper Jaffray raised its price target for Eagle Pharmaceuticals (EGRX) to $75 saying there is a "reasonably strong probability" the company will launch next year EP-6101, its ready-to-use form of The Medicines Company's (MDCO) Angiomax. Piper believes the outcome of Hospira's (HSP) litigation with The Medicines Co. should not have much bearing on Eagle's ability to enter the Angiomax market. It keeps an Overweight rating on Eagle Pharmaceuticals.
News For EGRX;MDCO;HSP From the Last 2 Days
There are no results for your query EGRX;MDCO;HSP
